Capmatinib dihydrochloride hydrate

• CAT Number: I024018
• CAS Number: 1865733-40-9
• Molecular Formula: C23H21Cl2FN6O2
• Molecular Weight: 503.36
• Purity: ≥95%
• Synonyms: 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;hydrate;dihydrochloride
• InChI: InChI=1S/C23H17FN6O.2ClH.H2O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20;;;/h2-9,11-13H,10H2,1H3,(H,25,31);2*1H;1H2
• InChIKey: COWBUPJEEDYWKD-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F.O.Cl.Cl

Capmatinib dihydrochloride hydrate（Cat No.:I024018）is a potent, selective inhibitor of MET (mesenchymal-epithelial transition factor) receptor tyrosine kinase, which plays a critical role in cancer cell growth, survival, and metastasis. By targeting MET mutations or amplifications, Capmatinib blocks signaling pathways that drive tumor progression, making it particularly effective in treating MET-driven cancers, such as non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Capmatinib dihydrochloride hydrate has demonstrated efficacy in clinical trials, offering a targeted treatment option for patients with MET-driven tumors who have limited therapeutic alternatives.